Birungi Josephine, Min Jeong Eun, Muldoon Katherine A, Kaleebu Pontiano, King Rachel, Khanakwa Sarah, Nyonyintono Maureen, Chen YaLin, Mills Edward J, Lyagoba Fred, Ragonnet-Cronin Manon, Wangisi Jonathan, Lourenco Lillian, Moore David M
The AIDS Support Organisation, Kampala, Uganda.
BC Centre for Excellence in HIV/ AIDS, Vancouver, Canada.
PLoS One. 2015 Jul 14;10(7):e0132182. doi: 10.1371/journal.pone.0132182. eCollection 2015.
We examined the real-world effectiveness of ART as an HIV prevention tool among HIV serodiscordant couples in a programmatic setting in a low-income country.
We enrolled individuals from HIV serodiscordant couples aged ≥18 years of age in Jinja, Uganda from June 2009 - June 2011. In one group of couples the HIV positive partner was receiving ART as they met clinical eligibility criteria (a CD4 cell count ≤250 cells/ μL or WHO Stage III/IV disease). In the second group the infected partner was not yet ART-eligible. We measured HIV incidence by testing the uninfected partner every three months. We conducted genetic linkage studies to determine the source of new infections in seroconverting participants.
A total of 586 couples were enrolled of which 249 (42%) of the HIV positive participants were receiving ART at enrollment, and an additional 99 (17%) initiated ART during the study. The median duration of follow-up was 1.5 years. We found 9 new infections among partners of participants who had been receiving ART for at least three months and 8 new infections in partners of participants who had not received ART or received it for less than three months, for incidence rates of 2.09 per 100 person-years (PYRs) and 2.30 per 100 PYRs, respectively. The incidence rate ratio for ART-use was 0.91 (95% confidence interval 0.31-2.70; p=0.999). The hazard ratio for HIV seroconversion associated with ART-use by the positive partner was 1.07 (95% CI 0.41-2.80). A total of 5/7 (71%) of the transmissions on ART and 6/7 (86%) of those not on ART were genetically linked.
Overall HIV incidence was low in comparison to previous studies of serodiscordant couples. However, ART-use was not associated with a reduced risk of HIV transmission in this study.
我们在一个低收入国家的项目环境中,研究了抗逆转录病毒疗法(ART)作为一种艾滋病毒预防工具在血清学不一致夫妻中的实际效果。
2009年6月至2011年6月,我们在乌干达金贾招募了年龄≥18岁的血清学不一致夫妻中的个体。在一组夫妻中,艾滋病毒呈阳性的伴侣因符合临床标准(CD4细胞计数≤250个/微升或世界卫生组织III/IV期疾病)而接受抗逆转录病毒疗法。在第二组中,受感染的伴侣尚未符合接受抗逆转录病毒疗法的条件。我们通过每三个月对未感染的伴侣进行检测来测量艾滋病毒发病率。我们进行了基因连锁研究,以确定血清转化参与者中新感染的来源。
共招募了586对夫妻,其中249名(42%)艾滋病毒呈阳性的参与者在入组时接受抗逆转录病毒疗法,另有99名(17%)在研究期间开始接受抗逆转录病毒疗法。随访的中位持续时间为1.5年。我们在接受抗逆转录病毒疗法至少三个月的参与者的伴侣中发现了9例新感染,在未接受抗逆转录病毒疗法或接受时间少于三个月的参与者的伴侣中发现了8例新感染,发病率分别为每100人年2.09例和每100人年2.30例。使用抗逆转录病毒疗法的发病率比为0.91(95%置信区间0.31 - 2.70;p = 0.999)。阳性伴侣使用抗逆转录病毒疗法与艾滋病毒血清转化相关的风险比为1.07(95%置信区间0.41 - 2.80)。接受抗逆转录病毒疗法的传播中有5/7(71%)以及未接受抗逆转录病毒疗法的传播中有6/7(86%)在基因上是相关的。
与先前对血清学不一致夫妻的研究相比,总体艾滋病毒发病率较低。然而,在本研究中,使用抗逆转录病毒疗法与降低艾滋病毒传播风险无关。